Onconetix Financial Statements From 2010 to 2025

ONCO Stock  USD 0.53  0.02  3.92%   
Onconetix financial statements provide useful quarterly and yearly information to potential Onconetix investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Onconetix financial statements helps investors assess Onconetix's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Onconetix's valuation are summarized below:
Gross Profit
-837.4 K
Market Capitalization
4.4 M
Enterprise Value Revenue
7.4999
Revenue
1.5 M
Earnings Share
(90.19)
We have found one hundred seventeen available trending fundamental ratios for Onconetix, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Onconetix's recent fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.

Onconetix Total Revenue

70,596.49

Check Onconetix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Onconetix's main balance sheet or income statement drivers, such as Interest Income of 0.0, Depreciation And Amortization of 53.1 K or Other Operating Expenses of 43.6 M, as well as many indicators such as Price To Sales Ratio of 1.9 K, Dividend Yield of 0.0 or PTB Ratio of 2.53. Onconetix financial statements analysis is a perfect complement when working with Onconetix Valuation or Volatility modules.
  
Check out the analysis of Onconetix Correlation against competitors.
To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.

Onconetix Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets105.7 M100.6 M24.3 M
Slightly volatile
Other Current Liabilities1.5 M2.4 M679.3 K
Slightly volatile
Total Current Liabilities20.8 M19.8 MM
Slightly volatile
Total Stockholder Equity70.8 M67.4 M17.8 M
Slightly volatile
Property Plant And Equipment Net252.6 K240.6 K50.8 K
Slightly volatile
Accounts Payable6.4 M6.1 M1.3 M
Slightly volatile
Cash9.4 M5.2 MM
Pretty Stable
Non Current Assets Total98.6 M93.9 M17.2 M
Slightly volatile
Non Currrent Assets Other463.1 K441.1 K107.2 K
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile
Cash And Short Term Investments9.4 M5.2 MM
Pretty Stable
Net Receivables180.8 K172.2 K51.2 K
Slightly volatile
Common Stock Shares Outstanding13.7 M19.7 M12.2 M
Slightly volatile
Liabilities And Stockholders Equity105.7 M100.6 M24.3 M
Slightly volatile
Other Stockholder Equity58.9 M56.1 M18.1 M
Slightly volatile
Total Liabilities28 M26.7 M5.3 M
Slightly volatile
Total Current Assets10.1 M6.7 M7.3 M
Slightly volatile
Common Stock27526266.6569
Slightly volatile
Net Invested CapitalM4.8 M5.9 M
Slightly volatile
Property Plant And Equipment Gross252.6 K240.6 K56.3 K
Slightly volatile
Capital Stock27526289.9069
Slightly volatile
Short and Long Term Debt Total7.9 M8.9 M9.7 M
Slightly volatile
Long Term Debt95.1 K107 K116.6 K
Slightly volatile
Short and Long Term Debt7.7 M8.7 M9.4 M
Slightly volatile
Non Current Liabilities Other691.2 K777.6 K847.8 K
Slightly volatile
Short Term Debt7.8 M8.8 M9.6 M
Slightly volatile
Intangible Assets20.3 M22.9 M24.9 M
Slightly volatile

Onconetix Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization53.1 K50.5 K10.5 K
Slightly volatile
Other Operating Expenses43.6 M41.5 M9.3 M
Slightly volatile
Research Development1.8 M2.2 M783.1 K
Slightly volatile
Cost Of Revenue1.4 M1.4 M250.1 K
Slightly volatile
Total Operating Expenses42.2 M40.1 MM
Slightly volatile
Selling General Administrative17.8 M17 M4.6 M
Slightly volatile
Reconciled Depreciation53.1 K50.5 K12 K
Slightly volatile
Selling And Marketing Expenses1.6 M1.8 M1.9 M
Slightly volatile

Onconetix Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation53.1 K50.5 K10.5 K
Slightly volatile
Capital Expenditures66.5 K63.3 K15.8 K
Slightly volatile
End Period Cash Flow9.4 M5.2 MM
Pretty Stable
Stock Based Compensation360.3 K379.2 K428.6 K
Pretty Stable
Begin Period Cash Flow31.1 M29.6 M10 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.9 K2.1 K2.3 K
Slightly volatile
PTB Ratio2.532.664.1 K
Pretty Stable
Days Sales Outstanding748841917
Slightly volatile
Book Value Per Share3.553.381.1565
Slightly volatile
Average Payables983.7 K936.9 K300.4 K
Slightly volatile
Stock Based Compensation To Revenue4.515.085.5346
Slightly volatile
Capex To Depreciation1.371.445.5145
Slightly volatile
PB Ratio2.532.664.1 K
Pretty Stable
EV To Sales1.9 K2.2 K2.4 K
Slightly volatile
Payables Turnover0.210.20.0627
Slightly volatile
Sales General And Administrative To Revenue202227248
Slightly volatile
Research And Ddevelopement To Revenue26.6730.0132.7177
Slightly volatile
Capex To Revenue0.750.850.9238
Slightly volatile
Cash Per Share0.230.240.5549
Very volatile
Days Payables Outstanding1.4 K1.5 K15.9 K
Pretty Stable
Income Quality0.810.420.8725
Slightly volatile
Intangibles To Total Assets0.740.830.9088
Slightly volatile
Current Ratio0.370.3954.7725
Slightly volatile
Receivables Turnover0.310.350.3829
Slightly volatile
Graham Number12.2711.683.4571
Slightly volatile
Shareholders Equity Per Share3.243.081.0976
Slightly volatile
Debt To Equity0.140.150.1657
Slightly volatile
Capex Per Share0.0030.00290.001
Slightly volatile
Average Receivables58.1 K83.5 K44.9 K
Slightly volatile
Revenue Per Share0.00270.00310.0034
Slightly volatile
Interest Debt Per Share0.50.560.6061
Slightly volatile
Debt To Assets0.0880.10.1106
Slightly volatile
Price Book Value Ratio2.532.664.1 K
Pretty Stable
Days Of Payables Outstanding1.4 K1.5 K15.9 K
Pretty Stable
Ebt Per Ebit0.790.930.9421
Very volatile
Effective Tax Rate4.0E-44.0E-40.0083
Pretty Stable
Company Equity Multiplier1.11.341.1497
Slightly volatile
Long Term Debt To Capitalization0.00160.00180.002
Slightly volatile
Total Debt To Capitalization0.110.130.1412
Slightly volatile
Debt Equity Ratio0.140.150.1657
Slightly volatile
Quick Ratio0.350.3754.7717
Slightly volatile
Net Income Per E B T0.80.90.981
Slightly volatile
Cash Ratio0.290.354.3749
Slightly volatile
Days Of Sales Outstanding748841917
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0198
Slightly volatile
Price To Book Ratio2.532.664.1 K
Pretty Stable
Fixed Asset Turnover0.220.250.2739
Slightly volatile
Debt Ratio0.0880.10.1106
Slightly volatile
Price Sales Ratio1.9 K2.1 K2.3 K
Slightly volatile
Asset Turnover5.0E-46.0E-47.0E-4
Slightly volatile
Price Fair Value2.532.664.1 K
Pretty Stable

Onconetix Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap108.4 M122 M133 M
Slightly volatile
Enterprise Value112.7 M126.8 M138.2 M
Slightly volatile

Onconetix Fundamental Market Drivers

Cash And Short Term Investments4.6 M

Onconetix Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Onconetix Financial Statements

Onconetix investors utilize fundamental indicators, such as revenue or net income, to predict how Onconetix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue1.4 M1.4 M
Total Revenue67.2 K70.6 K
Stock Based Compensation To Revenue 5.08  4.51 
Sales General And Administrative To Revenue 227.38  202.11 
Research And Ddevelopement To Revenue 30.01  26.67 
Capex To Revenue 0.85  0.75 
Ebit Per Revenue(554.71)(582.45)

Pair Trading with Onconetix

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.

Moving together with Onconetix Stock

  0.75EQ EquilliumPairCorr
  0.88ME 23Andme HoldingPairCorr
  0.87VALN Valneva SE ADRPairCorr

Moving against Onconetix Stock

  0.94VCEL Vericel Corp OrdPairCorr
  0.86VCYT Veracyte Potential GrowthPairCorr
  0.69DRTS Alpha Tau MedicalPairCorr
  0.64DMAC DiaMedica TherapeuticsPairCorr
  0.56SABSW SAB BiotherapeuticsPairCorr
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Onconetix offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Onconetix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Onconetix Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Onconetix Stock:
Check out the analysis of Onconetix Correlation against competitors.
To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(90.19)
Revenue Per Share
2.892
Return On Assets
(0.22)
Return On Equity
(17.58)
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.